High expectations of the new Bayer boss
Von
Bill Anderson, pictured here as CEO of Roche Pharmaceuticals, 2019 Bild: dpa
Werner Baumann’s successor has to deal with conflicting interests. One stands for the conglomerate, the other for a split.
The capital market got what it asked for. The replacement of Werner Baumann as CEO is faster than planned, and with Bill Anderson, a manager from outside comes to the top of the pharmaceutical and agrochemical group Bayer. So one who has nothing to do with the controversial purchase of the American seed company Monsanto had to do. As a US citizen, Anderson knows the rules of the game in one of the most important countries for Bayer.
The chemical engineer, who was last on the board of the Swiss pharmaceutical company Roche According to the plan of the Supervisory Board, which unanimously appointed him as the new CEO effective June 1, innovations should be accelerated and performance improved in all business areas.
€2.95 / week
Subscribe now for free access?
You can read this and many other articles exclusively with F+
What: FAZ